Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1244
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 853–864 of 1,244 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional Results available

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

NCT04214249
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Echocardiography Test, Hematopoietic Cell Transplantation, Idarubicin Hydrochloride, Multigated Acquisition Scan, Pembrolizumab, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Active, not recruiting No phase listed Observational

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

NCT05611918
Site status not listed — check the official record
View directory record Official record
Conditions
Intra Cerebral Hemorrhage, ICH - Intracerebral Hemorrhage, ICH, Hemorrhage, Stroke, Clot (Blood); Brain, Clot Blood, Cognitive Decline, Cognitive Impairment, Survivorship, Memory Impairment, Motor Activity
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Recruiting Not applicable Interventional

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

NCT07019259
Status at this site: Recruiting
View directory record Official record
Conditions
Cancer, Childhood Cancer, Chemotherapy-induced Peripheral Neuropathy
Interventions
Anodyne Therapy System
Device
Lead sponsor
Yale University
Other
Eligibility
5 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Trumbull, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Active, not recruiting Phase 3 Interventional

S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

NCT04155034
Site status not listed — check the official record
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
Interventions
Magnetic Resonance Imaging, Prophylactic Cranial Irradiation
Procedure · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
428
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Phosphodiesterase 4B (PDE4B) in People With Psychiatric Disorders With Positron Emission Tomography (PET) and the Radiotracer [18F]PF974

NCT07488819
Status at this site: Recruiting
View directory record Official record
Conditions
Post-Traumatic Stress Disorder, PTSD, Alcohol Use Disorder (AUD)
Interventions
PF974
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Recruiting Not applicable Interventional

Adaptive Decision Support for Addiction Treatment Master

NCT06799117
Status at this site: Recruiting
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
EMBED CDS, Nurse prompt to complete COWS, Provider Prompt, Patient facing materials, Optimized EMBED, Name of Intervention
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Guilford, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

NCT04251416
Site status not listed — check the official record
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
Sacituzumab Govitecan
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Active, not recruiting Phase 1 Interventional

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

NCT02503722
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Osimertinib, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Recruiting Phase 2 Interventional

Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

NCT05313243
Status at this site: Recruiting
View directory record Official record
Conditions
T-Cell Lymphoma
Interventions
Brentuximab vedotin, Pembrolizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Recruiting Phase 2 Interventional

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

NCT05317000
Status at this site: Recruiting
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Combination 5-azacytidine and nivolumab, Nivolumab
Drug
Lead sponsor
Barbara Burtness
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Recruiting Phase 3 Interventional

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

NCT05561387
Status at this site: Recruiting
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
397
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

NCT06106672
Site status not listed — check the official record
View directory record Official record
Conditions
Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
Interventions
CNP-106, Placebo
Drug · Other
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Brea, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 27, 2026, 1:27 PM EDT

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.